| Drug / Therapy | Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients |
| Indication | — |
| Decision Type | Early Phase 1 |
| Trial Phase | Early Phase 1 |
| ClinicalTrials.gov | NCT06292650 |
Profound Medical (PRN) operates in the TULSA-PRO Prostate sector. The current BTS Score is 35 (Grade: D).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Early Phase 1 date for Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients by Profound Medical (PRN) is scheduled for December 25, 2027. This is the target date for the FDA to make a decision on this application.
Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients is being developed by Profound Medical for the treatment of its target indication. It is currently in Early Phase 1 clinical trials.
If Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients receives FDA approval, Profound Medical (PRN) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Early Phase 1 date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for PRN on DilutionWatch at dilutionwatch.com/stock/PRN.html.
You can view the full BiotechSigns company profile for Profound Medical (PRN) at biotechsign.com/app/company/PRN, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.